Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00187577
Status:
COMPLETED
Last Update Posted:
2011-06-09
First Post:
2005-09-13
Brief Title:
Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Efficacy and Safety of Latanoprost Xalatan and Bimatoprost Lumigan Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single center randomized investigator-masked study to determine the efficacy and safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer darker and thicker eyelashes with their use In this study patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day
Detailed Description:
This is a pilot single-center randomized investigator-masked study to evaluate the efficacy and safety of latanoprost Xalatan ophthalmic solution compared to bimatoprost Lumigan ophthalmic solution in patients with eyelash loss due to alopecia areata This is a collaborative study between the Departments of Dermatology and Ophthalmology at UCSF Patients will be randomized to receive either latanoprost or bimatoprost Patients will be instructed to apply latanoprost or bimatoprost to the affected eyelid margins of one eye using a sterile cotton-tipped applicator once a day similar to the application of eyeliner The untreated eye will serve as a control When substantial eyelash growth is noted in the treated eye patients will be instructed to decrease application to once a week Patients will be seen every four weeks in the Department of Dermatology In addition eyelash growth will be assessed in the Beckman Vision Center where eyelash length will be measured and photographs will be taken at baseline 2 months and 4 months Intraocular pressure will be documented at baseline and at each visit to the Beckman Vision Center The study will be conducted over four months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None